AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11502237
Drug: Yoghurt-based drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoghurt-based drink enriched with 1 g plant sterol extracted from soyabean/d
Trial: 11502237
Drug: Yoghurt-based drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoghurt-based drink enriched with 2 g plant sterols/d
Trial: 9041099
Drug: Ursodiol (13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodiol (13 to 15 mg per kilogram of body weight per day in divided doses)
Trial: 1978115
Drug: L1 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L1 (50 mg/kg daily by mouth)
Trial: 1978115
Drug: Desferrioxamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferrioxamine (50 mg/kg daily as a 12 h subcutaneous infusion)
Trial: 29938533
Drug: Ranolazine (6-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine (6-week add-on therapy)
Trial: 29938533
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without additional study medication (Control)
Trial: 28658582
Drug: Acute nitrate
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute nitrate supplementation (10 mg·kg‐1 body mass of sodium nitrate)
Trial: 23666445
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of ascorbic acid (7.5 g)
Trial: 17374416
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate 50 mg daily for 30 days
Trial: 11782329
Drug: IT fentanyl
RxNorm normalized name: IT-139
DrugBank: IT-139 (DB17145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT fentanyl 25 microg plus plain bupivacaine 1.25 mg (Group f+pb)
Trial: 11782329
Drug: IT fentanyl
RxNorm normalized name: IT-139
DrugBank: IT-139 (DB17145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT fentanyl 25 microg plus heavy bupivacaine 1.25 mg (Group f+hb)
Trial: 9824781
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg intravenously
Trial: 8799530
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg orally
Trial: 9824781
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg intravenously or 40 mg orally every 12 hours
Trial: 8861410
Drug: Behavioural treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural treatment including applied relaxation, video self‐modelling, exposure, information, and teaching of hearing tactics
Trial: 7086742
Drug: Behavioural treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural treatment
Trial: 2667324
Drug: epirubicin 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epirubicin 90 mg/m2 (75 mg/m2 if prior radiotherapy) i.v. once every 3 weeks
Trial: 2667324
Drug: 5-fluorouracil 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil 500 mg/m2 (450 mg/m2 if prior radiotherapy) i.v. once daily for 5 consecutive days every 4 weeks
Trial: 1106936
Drug: 220 mg
RxNorm normalized name: urea 220 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 220 mg of naproxen
Trial: 1106936
Drug: 330 mg
RxNorm normalized name: urea 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 330 mg of naproxen
Trial: 30559067
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (systemically administered opioids)
Trial: 23647445
Drug: Fingolimod 0.5
RxNorm normalized name: fingolimod 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 0.5 mg once daily for 6 months
Trial: 21596735
Drug: L-arginine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine plus antioxidant vitamins
Trial: 11427637
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (MB) given as a bolus of 1 mg/kg bodyweight followed by a constant infusion of 0.1 mg/kg bodyweight for 210 min during dialysis
Trial: 9531074
Drug: Meropenem (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (0.5 g 8-hourly)
Trial: 9531074
Drug: Ceftazidime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (1 g 8-hourly)
Trial: 8028055
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (TPN)
Trial: 8028055
Drug: Parenteral plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral plus enteral nutrition (PN/EN)
Trial: 30911756
Drug: 2× daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2× daily feeding (half ration at 0730 and 1530 h)
Trial: 30911756
Drug: 3× daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3× daily feeding (a third portion at 0730, 1130, and 1530 h)
Trial: 30911756
Drug: 2× daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2× daily feeding
Trial: 30911756
Drug: 3× daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3× daily feeding
Trial: 24178238
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch (2 mg/24 h) applied for 24 h
Trial: 20031846
Drug: Uncertainty reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncertainty reduction intervention (provided in 5 clinics) including access to a specially designed study form with blood pressure graphs, assessment checkboxes, and a menu of services (24-hour ambulatory blood pressure monitoring, electronic bottle cap assessment of medication adherence, lifestyle assessment and counseling).
Trial: 20430601
Drug: Ciclesonide 80
RxNorm normalized name: CICLESONIDE 80MCG 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide 80 microg once daily
Trial: 14977388
Drug: Ciclesonide 320
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide 320 microg daily
Trial: 14977388
Drug: Ciclesonide 80
RxNorm normalized name: CICLESONIDE 80MCG 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide 80 or 320 microg daily
Trial: 9741504
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and oral atenolol
Trial: 2525897
Drug: Oral atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral atenolol
Trial: 30552406
Drug: Telmisartan +
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan + Low-dose rosuvastatin
Trial: 30552406
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Low-dose rosuvastatin
Trial: 23801303
Drug: Cediranib 45
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib 45 mg/day plus fulvestrant
Trial: 19038708
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PC and BP
Trial: 15923042
Drug: Fluoxetine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine monotherapy 10-30 mg daily
Trial: 15923042
Drug: Olanzapine monotherapy
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine monotherapy 5-20 mg daily
Trial: 15923042
Drug: Combined fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined fluoxetine plus olanzapine therapy 10-40 mg plus 5-15 mg daily
Trial: 8794412
Drug: Chemo-immunotherapy (IL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-immunotherapy (IL-2 and LAK cells after two courses of anticancer chemotherapy)
Trial: 8794412
Drug: Chemotherapy (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (same anticancer chemotherapy as group A)
Trial: 3522507
Drug: Piracetam (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (3.3 g/day in two divided doses for 12 weeks)
Trial: 29341461
Drug: Exenatide infusion
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide infusion (Study-A)
Trial: 29341461
Drug: Exenatide infusion
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide infusion (Study-B)
Trial: 22622291
Drug: Propofol plus
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol plus Ketamine (1.5 mg/kg + 0.8 mg/kg)
Trial: 20394542
Drug: Topical anti-glaucoma
RxNorm normalized name: Anti Bac Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anti-glaucoma medications (AGM)
Trial: 20394542
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no topical medications)
Trial: 18588760
Drug: Local decongestant
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local decongestant
Trial: 18588760
Drug: Vardenafil +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil + Local decongestant
Trial: 15965687
Drug: Whole-body (18)F‐FDG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body (18)F‐FDG PET after one or two courses of induction chemotherapy (IC)
Trial: 10520784
Drug: Abrupt cessation
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abrupt cessation of intravenous unfractionated heparin (UFH)
Trial: 10520784
Drug: Intravenous weaning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous weaning over 12 hours
Trial: 10520784
Drug: Subcutaneous weaning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous weaning over 12 hours
Trial: 2115686
Drug: Insulin Novo
RxNorm normalized name: INSULIN NOVOLIN 70/30 INJ PEN 3ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin Novo Protaphan HM Penfill (100 IU/ml 'bed time') and 10 mg of glibenclamide in the morning (group A)
Trial: 2115686
Drug: Insulin Novo
RxNorm normalized name: INSULIN NOVOLIN 70/30 INJ PEN 3ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin Novo Actraphan HM Penfill (100 IU/ml in the morning) combined with two 5 mg doses of glibenclamide at lunchtime and in the evening (group B)
Trial: 29735813
Drug: L-tyrosine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tyrosine (100 mg/kg/day)
Trial: 19564995
Drug: TIMER (Tool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIMER (Tool to Improve Medications in the Elderly via Review)
Trial: 15327641
Drug: Rinsing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinsing with a sucrose solution
Trial: 15327641
Drug: Rinsing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinsing with water, a commercially available fluoride mouthrinse without antimicrobial agents, or brushing with a fluoride dentifrice
Trial: 11194173
Drug: Soft gelatin
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gelatin capsules containing 300 mg of alcoholic Hypericum extract (5% hyperforin and 0.3% hypericin)
Trial: 11194173
Drug: Hard gelatin
RxNorm normalized name: Hard Gelatin Capsule Shell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard gelatin capsules (standard formulation)
Trial: 11194173
Drug: Soft gelatin
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gelatin capsules
Trial: 2442553
Drug: Lisinopril 40-80
RxNorm normalized name: lisinopril 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 40-80 mg/day
Trial: 2442553
Drug: Metoprolol 100-200
RxNorm normalized name: metoprolol tartrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100-200 mg/day
Trial: 22236346
Drug: Chloroprocaine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroprocaine (40 mg) mixed with 12.5 μg of fentanyl
Trial: 22236346
Drug: Lidocaine (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (35 mg) mixed with 12.5 μg of fentanyl
Trial: 20350785
Drug: Meloxicam 7.5
RxNorm normalized name: meloxicam 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam 7.5 mg orally twice per day starting on the day of implant
Trial: 20350785
Drug: Meloxicam 7.5
RxNorm normalized name: meloxicam 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam 7.5 mg orally twice per day starting 1 week prior to implant
Trial: 8897116
Drug: Drug-free depressed
RxNorm normalized name: Malmea depressa bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free depressed patients
Trial: 6615751
Drug: Topical antiprostaglandins
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antiprostaglandins
Trial: 24403544
Drug: Hib conjugate
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hib conjugate vaccine booster
Trial: 15319388
Drug: Assisted hatching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assisted hatching using acidic Tyrode's solution
Trial: 11453889
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (DHE) 0.5 mg
Trial: 7798824
Drug: Coumadin (adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coumadin (adjusted dosage to maintain INR between 1.5-3)
Trial: 7798824
Drug: Aspirin (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (fixed dosage of 75 mg per day)
Trial: 31816097
Drug: eIL-31-CuMVTT vaccine
RxNorm normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eIL-31-CuMVTT vaccine (300 µg)
Trial: 26554758
Drug: 15 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g/day of alcohol
Trial: 26554758
Drug: 30 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g/day of alcohol
Trial: 26554758
Drug: 0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g/day of alcohol (control)
Trial: 21613574
Drug: β‐AR blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐AR blockade (intravenous propranolol)
Trial: 18468672
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with 525 microg of venom monthly after a 6-week build-up period
Trial: 12747499
Drug: DHEA 50
RxNorm normalized name: Natrol Mood & Stress DHEA 50mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 50 mg/day for 4 weeks
Trial: 1552057
Drug: High-dose UVA1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose UVA1 irradiation (130 joules/cm2)
Trial: 1552057
Drug: High-dose UVA1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose UVA1 irradiation
Trial: 10068928
Drug: UVA-UVB therapy
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVA-UVB therapy
Trial: 22149257
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of fluindione
Trial: 22149257
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of acenocoumarol
Trial: 18794727
Drug: PPARgamma agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPARgamma agonists (muraglitazar and other 10 PPARgamma agonists)
Trial: 18794727
Drug: PPARgamma agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPARgamma agonists (one of three previously uncharacterized PPARgamma agonists)
Trial: 12127877
Drug: Interleukin-2 as
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interleukin-2 as adjunctive therapy to antiretroviral therapy
Trial: 10772563
Drug: Mixed administration
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed administration of DTPw-HBV and Hib vaccines
Trial: 10772563
Drug: Separate administration
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate administration of DTPw-HBV and Hib vaccines
Trial: 8545872
Drug: Steroid Withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid Withdrawal (SW) group
Trial: 347884
Drug: Bromperidol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromperidol (1 mg tablets, initial dose: 1 mg, mean dose at end: 4.47 mg)
Trial: 29331031
Drug: Bladder body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bladder body injection of 100U BoNT‐A in 10 mL saline
Trial: 29331031
Drug: Trigonal injection
RxNorm normalized name: ERGONAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigonal injection of 100U BoNT‐A in 10 mL saline
Trial: 26193635
Drug: Alefacept (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alefacept (two 12-week courses of 15 mg/wk i.m., separated by a 12-week pause)
Trial: 23771104
Drug: BMS-986001 100
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986001 100 mg
Trial: 23771104
Drug: BMS-986001 200
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986001 200 mg
Trial: 23771104
Drug: BMS-986001 300
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986001 300 mg
Trial: 23771104
Drug: BMS-986001 600
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986001 600 mg
Trial: 10752802
Drug: Additional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional therapy with colloid and dobutamine (5 microg/kg/min then 10 microg/kg/min) for patients with pHi <7.35
Trial: 10752802
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard resuscitation without additional therapy)
Trial: 10752802
Drug: Additional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional therapy with colloid and dobutamine for patients with gastric mucosal pH of > or =7.35 at admission
Trial: 10752802
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard resuscitation without additional therapy) for patients with gastric mucosal pH of > or =7.35 at admission
Trial: 8694326
Drug: Epidural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural sufentanil infusion at lumbar level (1 microgram/mL)
Trial: 8694326
Drug: Epidural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural sufentanil infusion at thoracic level (1 microgram/mL)
Trial: 8694326
Drug: Epidural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural sufentanil combined with bupivacaine at thoracic level (1 mg/mL)
Trial: 6374885
Drug: Sclerotherapy (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sclerotherapy (20 ml Aethoxysclerol 1%)
Trial: 24800998
Drug: FE 999049
RxNorm normalized name: Fe
DrugBank: Ferric cation (DB13949)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FE 999049 (recombinant follicle-stimulating hormone from human cell line)
Trial: 20087375
Drug: Salba (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salba (0, 7, 15 or 24 g baked into white bread)
Trial: 7856520
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (48-hour treatment)
Trial: 28975821
Drug: Long-acting blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting blood cardioplegia (adenosine 12 mg via aortic root, followed by a single dose of long-acting solution at 14℃, 30 mL/kg)
Trial: 28975821
Drug: St. Thomas'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. Thomas' cardioplegia (initial 30 mL/kg at 14℃, followed by 15 mL/kg every 20 min)
Trial: 21955930
Drug: Nicotine patches
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patches (experimental group)
Trial: 21955930
Drug: No nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No nicotine patches (control group)
Trial: 25338188
Drug: Concurrent feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent feedback
Trial: 15080061
Drug: Intraprostatic injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAPROSTATIC LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraprostatic injection of Chuanshentong (6 ml mixed with lidocaine, once a day for 6 days)
Trial: 15080061
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection containing lidocaine
Trial: 2842137
Drug: Flumazenil (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (1.0 mg i.v.)
Trial: 2842137
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia with midazolam and alfentanil